Glucose Consumption During Deep Brain Stimulation With Functional [18F]FDG-Brain-PET in Obsessive-Compulsive Disorder
Condition(s) studied
Investigational drug(s) / intervention(s)
Implantation of a DBS therapy system: The system is called "Reclaim DBS Therapy for OCD" und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula.
Study summary
The purpose of this randomized, sham-controlled study is to evaluate the effectiveness of DBS therapy in individuals suffering from severe OCD and to investigate DBS treatment with functional \[18F\]FDG-Brain-PET.
Eligibility
Primary outcome measure(s)
- Change of metabolic rates of glucose response pattern — fPET measurements will take place in Week 4 and Week 5 of the trial.
Change of metabolic rates of glucose response pattern
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Medical University of Vienna, Department of Psychiatry and Psychotherapy | Vienna | State of Vienna | Recruiting |
More Medical University of Vienna trials in Austria
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05577598 on ClinicalTrials.gov ↗ ← All trials in Austria